|Day Low/High||50.81 / 53.97|
|52 Wk Low/High||13.50 / 61.24|
The bears are likely to be increasingly bold if there's a failed bounce.
Jim Cramer highlights Anthem, A.O. Smith, Tableau Software, Electro Scientific Industries, CRISPR Therapeutics.
Jim Cramer says this is the scary process that gets us back to where we can maintain a real, not parabolic, advance.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) today announced that the companies will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as...
CRISPR gene-editing in hematopoietic stem cells demonstrates potential to treat ß-thalassemia and sickle cell disease through upregulation of fetal hemoglobin
-Phase 1/2 trial in ß-thalassemia expected to begin in 2018-
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APEI, CMP, FRPT, GLP, OPHT, SEE, TA, TIS, VRTS Downgrades: BCRH, CAFD, KO, REGN, TERP Initiations: CRSP Read on to get TheStreet Quant Ratings' detailed report:
CureVac's mRNA technology accessed to express Cas9 for in vivo liver-targeted therapies
-FARA and CRISPR Celebrate Annual rideATAXIA Event-
Company President to assume CEO role effective December 1, 2017
Collaboration expands CRISPR Therapeutics' efforts in immuno-oncology
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.